HKG:1548

4 stories mentioning HKG:1548Updated 9d ago

Every FINWIRES story that references HKG:1548, newest first.

Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma

Genscript Biotech (HKG:1548) said its Nasdaq-listed associate Legend Biotech established clinical proof-of-concept for LB2501 in a type of blood cancer, according to a Sunday filing with the Hong Kong bourse.According to results from an ongoing phase 1 trial presented at the annual European Hematology Association Congress, the drug achieved a 100% objective response rate at the higher dose level in the six subjects enrolled in the study with relapsed or refractory B-cell non-Hodgkin lymphoma.LB2501 also showed a favorable safety profile with no dose-limiting toxicities, the firm said.Shares of Genscript fell almost 9% in late morning trade on Monday.

HKG:1548

Asia21d ago

Genscript Associate to Present Data for Lymphoma Drug at European Conference; Shares Surge 11%

Genscript Biotech's (HKG:1548) associate Legend Biotech will present preliminary clinical data for LB2501 at a late-breaking session at the European Hematology Association 2026 Congress, according to a Tuesday Hong Kong bourse filing.Shares of the cancer drug company were up nearly 11% in Wednesday afternoon trading.The data is for the drug being tested in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.The conference will take place from June 11 to 14 in Stockholm, Sweden.

HKG:1548

Asia21d ago

Market Chatter: Genscript Biotech Defends Operations Amid Renewed U.S. Lawmaker Scrutiny

Genscript Biotech (HKG:1548) defended its operations after renewed scrutiny from U.S. lawmakers over alleged national security concerns, the South China Morning Post reported Wednesday.The company said it operates with transparency across its global markets and follows strict data security and intellectual property safeguards, according to the report.The response came after two U.S. lawmakers reportedly sent a letter to the Federal Bureau of Investigation and the Office of the Director of National Intelligence for updated information regarding GenScript and its affiliates.The lawmakers had made a similar request last year, citing concerns about potential links to China's biotechnology ambitions.Shares of the life sciences firm were up over 14% in Wednesday afternoon trade.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

HKG:1548

Asia71d ago

Genscript Biotech Associate Logs $597 Million in Q1 Sales of Carvykti

Genscript Biotech (HKG:1548) associate Legend Biotech said Carvykti generated around $597 million in net trade sales in the quarter ended March 31, according to a Tuesday Hong Kong bourse filing.The sales were recorded under a collaboration and license agreement between Legend Biotech and Janssen Biotech dated Dec. 21, 2017.

HKG:1548

Track with the FINWIRES app suite

FolioX

Track HKG:1548 in your portfolio

WheelAI

Analyze HKG:1548 options with the wheel strategy

StockInsider

See market sentiment on HKG:1548